Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

  • Sarclisa administered via the CirCLIQ OBI offers a treatment experience designed around the needs of patients and HCPs and enables flexible administration in either home or outpatient settings
  • Sarclisa is the first anticancer treatment to be administered through an OBI and the first MM treatment available by both SC OBI and manual injection in the EU
  • Efficacy of Sarclisa demonstrated in SC formulation with innovative OBI across all indications and combinations currently approved for the IV formulation